Nurix Therapeutics, Inc. Common stock (NRIX)

Price$17.39

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-0.08%

Price vs S&P 500 (4W)0.68%

VGM Score49.50

Market Capitalization$1.84B

All Metrics

Book Value / Share (Quarterly)$4.65

P/TBV (Annual)0.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)29.54%

Cash Flow / Share (Quarterly)$-2.63

Price vs S&P 500 (YTD)-17.31%

Net Profit Margin (TTM)-411.37%

EPS (TTM)$-3.16

10-Day Avg Trading Volume1.28M

EPS Excl Extra (TTM)$-3.16

Revenue Growth (5Y)36.35%

EPS (Annual)$-3.05

ROI (Annual)-49.09%

Net Profit Margin (5Y Avg)-343.51%

Cash / Share (Quarterly)$5.23

Revenue Growth QoQ (YoY)-66.12%

ROA (Last FY)-38.43%

Revenue Growth TTM (YoY)27.23%

EBITD / Share (TTM)$-3.29

ROE (5Y Avg)-50.25%

Operating Margin (TTM)-439.26%

Cash Flow / Share (Annual)$-2.59

P/B Ratio3.82x

P/B Ratio (Quarterly)3.38x

Net Income / Employee (Annual)$-834,200

EV / Revenue (TTM)24.59x

ROA (TTM)-48.44%

EPS Incl Extra (Annual)$-3.05

Current Ratio (Annual)7.02x

Quick Ratio (Quarterly)5.86x

3-Month Avg Trading Volume1.08M

52-Week Price Return66.92%

Revenue / Employee (TTM)$226,400

Tangible BV / Share (Quarterly)$4.82

P/S Ratio (Annual)21.87x

Asset Turnover (Annual)0.12x

52-Week High$22.50

Operating Margin (5Y Avg)-360.87%

EPS Excl Extra (Annual)$-3.05

CapEx CAGR (5Y)25.21%

26-Week Price Return15.85%

Quick Ratio (Annual)6.86x

13-Week Price Return10.24%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.01x

Enterprise Value$1.77B

Revenue / Share Growth (5Y)16.14%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-6.64%

Revenue / Employee (Annual)$264,900

Pretax Margin (Annual)-314.00%

Cash / Share (Annual)$5.82

3-Month Return Std Dev45.14%

Net Income / Employee (TTM)$-931,500

ROE (Last FY)-49.09%

EPS Basic Excl Extra (Annual)$-3.05

P/FCF (TTM)76.19x

Receivables Turnover (TTM)68.62x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.16

Receivables Turnover (Annual)12.88x

ROI (TTM)-64.21%

P/S Ratio (TTM)25.59x

Pretax Margin (5Y Avg)-343.14%

Revenue / Share (Annual)$0.97

Tangible BV / Share (Annual)$6.44

Price vs S&P 500 (52W)38.71%

Year-to-Date Return-6.38%

5-Day Price Return1.49%

EPS Normalized (Annual)$-3.05

ROA (5Y Avg)-35.14%

Net Profit Margin (Annual)-314.90%

Month-to-Date Return6.35%

Cash Flow / Share (TTM)$-2.61

EBITD / Share (Annual)$-3.20

Operating Margin (Annual)-340.16%

ROI (5Y Avg)-50.25%

EPS Basic Excl Extra (TTM)$-3.16

P/TBV (Quarterly)1.29x

P/B Ratio (Annual)3.18x

Pretax Margin (TTM)-410.31%

Book Value / Share (Annual)$5.29

Price vs S&P 500 (13W)0.50%

Beta1.86x

Revenue / Share (TTM)$0.65

ROE (TTM)-64.21%

52-Week Low$8.20

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.30

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NRIXNurix Therapeutics, Inc. Common stock	D	C	B	$17.39
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and inflammatory diseases using an AI-enhanced discovery platform. The company's pipeline includes candidates such as Bexobrutideg and Zelebrudomide that target specific disease-causing proteins in immune and oncology-related pathways.